Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

Rhea-AI Summary

Lilly (NYSE: LLY) reported positive topline Phase 3 ADorable-1 results for EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis on March 16, 2026. At Week 16, EBGLYSS achieved EASI-75 63%, IGA 0,1 44%, EASI-90 39% and Pruritus NRS ≥4 improvement 35%. Safety was consistent with adult/adolescent studies, with no new signals and no injection site pain reported. Lilly plans regulatory submissions for potential pediatric label updates; the ADorable program and a 52-week extension continue.

Positive

• EASI-75 response of 63% at Week 16
• IGA 0,1 (clear/almost clear) in 44% of patients
• EASI-90 (near-complete clearance) in 39% of patients
• Pruritus NRS ≥4-point improvement in 35% of patients
• Safety profile consistent with adult/adolescent studies; no new signals

Negative

• Study required ongoing topical corticosteroids during the 16-week trial
• Primary data limited to Week 16 efficacy endpoint (short term)
• Regulatory approval not yet granted; label update is planned but pending

Key Figures

EASI-75 response: 63% EASI-75 placebo: 22% IGA 0,1 response: 44% +5 more

8 metrics

EASI-75 response 63% EBGLYSS arm, Week 16 in ADorable-1 Phase 3 pediatric study

EASI-75 placebo 22% Placebo arm, Week 16 in ADorable-1 study

IGA 0,1 response 44% EBGLYSS arm achieving clear/almost clear skin at Week 16

IGA 0,1 placebo 15% Placebo arm achieving clear/almost clear skin at Week 16

EASI-90 response 39% EBGLYSS arm, near-complete skin clearance at Week 16

EASI-90 placebo 11% Placebo arm, near-complete skin clearance at Week 16

Itch relief rate 35% EBGLYSS arm, Pruritus NRS ≥4-point improvement at Week 16

Pediatric prevalence 9.6 million children U.S. children with atopic dermatitis, all severities

Market Reality Check

Price: $985.08 Vol: Volume 1,980,703 is below...

normal vol

$985.08 Last Close

Volume Volume 1,980,703 is below the 20-day average of 2,795,206, suggesting limited pre-news positioning. normal

Technical Trading above 200-day MA at 887.64 and 13.13% below 52-week high of 1133.95.

Peers on Argus

LLY was up 0.8% while large-cap pharma peers like ABBV, JNJ, AZN, NVS and NVO sh...

LLY was up 0.8% while large-cap pharma peers like ABBV, JNJ, AZN, NVS and NVO showed declines between about -0.81% and -3.18%, indicating stock-specific strength rather than a sector-wide move.

Previous Clinical trial Reports

5 past events · Latest: Dec 18 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 18	Obesity trial data	Positive	+1.4%	Orforglipron Phase 3 weight maintenance met primary and key secondary endpoints.
Dec 11	Obesity/OA trial data	Positive	+1.6%	Retatrutide Phase 3 showed up to 28.7% weight loss and pain reduction.
Dec 07	CLL head-to-head trial	Positive	-1.3%	Jaypirca met non-inferiority vs Imbruvica with favorable safety profile.
Nov 24	CLL trial previews	Positive	+1.0%	Upcoming ASH presentations for two positive Phase 3 Jaypirca studies.
Nov 06	Obesity Phase 2 data	Positive	+1.3%	Eloralintide Phase 2 showed 9.5–20.1% weight loss versus 0.4% placebo.

Pattern Detected

Clinical trial announcements have usually seen modestly positive price reactions, with four aligned moves and one divergence.

Recent Company History

Recent clinical trial news for Eli Lilly has centered on obesity, oncology and hematology assets, with multiple Phase 2 and Phase 3 programs meeting primary and key secondary endpoints. Events since Nov 6, 2025 highlight meaningful weight loss from eloralintide, strong efficacy for Jaypirca in CLL/SLL, and positive data for retatrutide and orforglipron. Historically, these clinical milestones produced mostly positive one-day moves near +1%. The current pediatric atopic dermatitis results for EBGLYSS fit into this pattern of broadly favorable trial readouts.

Historical Comparison

+0.8% avg move · In the past year, Lilly’s clinical trial press releases around obesity and oncology averaged a 0.8% ...

clinical trial

+0.8%

Average Historical Move clinical trial

In the past year, Lilly’s clinical trial press releases around obesity and oncology averaged a 0.8% one-day move, suggesting markets typically react modestly to similar data updates.

The company has steadily advanced multiple late-stage programs, adding today’s positive pediatric atopic dermatitis Phase 3 results for EBGLYSS to prior obesity and hematology milestones.

Market Pulse Summary

This announcement details positive Phase 3 pediatric results for EBGLYSS, with high response rates s...

Analysis

This announcement details positive Phase 3 pediatric results for EBGLYSS, with high response rates such as 63% achieving EASI-75 and 39% reaching EASI-90 at Week 16 versus placebo. The safety profile was consistent with prior studies, with no injection site pain reported. In context of Lilly’s recent string of successful clinical readouts, investors may watch for regulatory submissions, label expansion decisions, and longer-term extension data from ADorable-2.

Key Terms

interleukin-13, cytokine, Eczema Area and Severity Index, monoclonal antibody

4 terms

interleukin-13 medical

"EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling"

Interleukin-13 is a small signaling protein produced by immune cells that tells other cells how to respond during allergies, asthma and certain types of tissue scarring; think of it as a text message that tells the body to dial up mucus, inflammation and repair processes. Investors watch it because drugs that block or measure interleukin-13 can change patient outcomes, drive clinical trial results, regulatory approvals, and revenue for companies developing therapies or diagnostics.

cytokine medical

"The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle"

Small proteins produced by cells that act as chemical messengers to coordinate immune and inflammatory responses, like text messages or traffic signals telling cells when to activate, calm down, or move. Investors care because cytokines are common drug targets and biomarkers; changes in cytokine activity can determine a therapy’s effectiveness, safety, regulatory approval, and market potential, so trial results or safety signals tied to cytokines often drive stock moves.

Eczema Area and Severity Index medical

"** | EASI=Eczema Area and Severity Index; EASI-75=75% reduction in EASI from baseline"

A standardized clinical score that measures how much skin is affected by eczema and how severe the lesions are, combining area and intensity into one number much like a report card for a skin condition. Investors care because changes in this score are often used as a primary measure of a treatment’s effectiveness in clinical trials, influencing regulatory approval chances, market potential, and the perceived value of companies developing eczema therapies.

monoclonal antibody medical

"eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. Not financial advice.

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16

In key secondary endpoints, 39% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 35% achieved significant itch relief (Pruritus NRS ≥4-point improvement)

The safety and tolerability profile of EBGLYSS was consistent with adult and adolescent studies, with no injection site pain reported

INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients with moderate-to-severe atopic dermatitis. EBGLYSS met the primary and key secondary endpoints at Week 16, improving disease severity while delivering skin clearance and relief from persistent itch. Atopic dermatitis is more common in children than adults, affecting 9.6 million children in the U.S., one-third of whom have moderate-to-severe disease.¹ Lilly plans to submit these data to U.S. and global regulators for a potential label update.

EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate.^2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.^5,6

In ADorable-1, participants were randomized to receive placebo or a weight-based dose of EBGLYSS. Topical corticosteroids were required beginning two weeks before randomization and throughout the 16-week study but could be decreased or stopped once patients achieved IGA 2 or less. The co-primary endpoints in ADorable-1 were EASI-75 and IGA 0,1 at Week 16. Key secondary endpoints included an even greater clinical improvement in disease severity (EASI-90) and itch relief (Pruritus NRS ≥4-point improvement).

Key efficacy results in ADorable-1 at Week 16
	EBGLYSS*	Placebo
EASI-75**	63 %	22 %
IGA 0,1 and a reduction ≥2 points from baseline†	44 %	15 %
EASI-90‡	39 %	11 %
Pruritus NRS ≥4-point improvement§ in patients 6 years and older with score ≥4 at baseline	35 %	6 %

*	Includes all EBGLYSS dosing regimens
**	EASI=Eczema Area and Severity Index; EASI-75=75% reduction in EASI from baseline
†	IGA 0,1=Investigator's Global Assessment 0 or 1 ("clear" or "almost clear")
‡	EASI-90=90% reduction in EASI from baseline
§	Pruritus NRS=Numeric Rating Scale rating itch from 0-10 with 10 being worst imaginable itch within the past 24 hours

"Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers," said Adrienne Brown, executive vice president and president, Lilly Immunology. "EBGLYSS has already changed what's possible for adults and adolescents, delivering durable results that help patients flare less with the option of monthly maintenance dosing. Now, these data show EBGLYSS also provided disease control in pediatric patients, a critical milestone that, if approved, could bring profound relief to these patients and their families."

The safety of EBGLYSS was consistent with the known profile in adult and adolescent patients, with no new safety signals observed. The most common adverse events occurring in ≥5% of participants were upper respiratory tract infections and nasopharyngitis, with no numerical imbalance between treatment groups. Injection site reactions were reported similarly in the EBGLYSS and placebo arms, with no injection site pain reported.

"Despite the high prevalence of moderate-to-severe atopic dermatitis in infants and young children, they have fewer approved treatment options than adults and adolescents," said Amy Paller, M.D., chair, department of dermatology at Northwestern University and ADorable study investigator. "The topline results from ADorable-1 offer hope for these young patients, delivering near-complete skin clearance and significant itch relief with a highly selective medicine that targets the underlying inflammation that drives this chronic disease."

The ADorable clinical program is ongoing. Additional results from ADorable-1 and ADorable-2, a 52-week extension study of patients enrolled in ADorable-1, will be disclosed later this year.

Lilly continues to raise the standard of care in dermatology and boldly invest in the next wave of immunology innovation, which includes big bets on next-generation modalities, the targeted expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsO and TOGETHER-PsA trials investigating the efficacy and safety of treating adults with psoriatic disease and obesity with both ixekizumab and an incretin-based therapy. Lilly's investigational therapies include DC-853, a novel oral IL-17 inhibitor being studied for psoriasis, and eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation and is being assessed in hidradenitis suppurativa.

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe.

About ADorable-1
ADorable‑1 (NCT05559359) is a randomized, double‑blind, placebo‑controlled Phase 3 study evaluating the efficacy and safety of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis, including infants and children as young as six months. Participants (N=363) were randomized to receive placebo or a weight-based dose of EBGLYSS. Topical corticosteroids were required beginning two weeks before randomization and throughout the 16-week study, but could be decreased or stopped once patients achieved IGA 2 or less. Data from ADorable‑1 are intended to support a potential label expansion of EBGLYSS in younger pediatric populations.

About EBGLYSS 
EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.^3,4,7 EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.⁷

The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating over 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin), adolescent open-label (ADore) and pediatric (ADorable 1 and 2) studies. Further data results from ADorable are expected later this year. EBGLYSS is also being studied in allergic rhinitis and chronic rhinosinusitis with nasal polyps.

EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment with the option of monotherapy that offers once-monthly maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.⁷  EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks) which can be used with or without topical corticosteroids.⁷

Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans. We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative. Through Lilly Support Services, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients.

INDICATION AND SAFETY SUMMARY 
EBGLYSS^® (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.

It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

Before using
Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:

• Have a parasitic (helminth) infection.
• Are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with EBGLYSS.
• Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy.
• Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Possible side effects
EBGLYSS can cause serious side effects, including:

• Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms:
  • breathing problems or wheezing
  • swelling of the face, lips, mouth, tongue or throat
  • hives
  • itching
  • fainting, dizziness, feeling lightheaded
  • skin rash
  • cramps in your stomach area (abdomen)

• Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision.

The most common side effects of EBGLYSS include:

• eye and eyelid inflammation, including redness, swelling, and itching
• injection site reactions
• shingles (herpes zoster)

These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How to take

• See the detailed "Instructions for Use" that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes.
• Use EBGLYSS exactly as prescribed by your healthcare provider.
• EBGLYSS is given as an injection under the skin (subcutaneous injection).
• If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver.
• If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time.

Learn more
EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com

This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you.

LK CON BS AD APP

EBGLYSS, its delivery device base, and Lilly Support Services are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements 
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about EBGLYSS (lebrikizumab-lbkz) as a treatment for patients with moderate-to severe atopic dermatitis and the timeline for future readouts, presentations, and other milestones relating to EBGLYSS and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date or that EBGLYSS will receive additional regulatory approvals, or that it will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1	Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73.
2	Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017
3	Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7
4	Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024
5	Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954
6	Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018
7	EBGLYSS. Prescribing Information. Lilly USA, LLC.

 

Refer to:	Kelly Hoffman; kelly.hoffman@lilly.com; 765-736-2555 (Lilly media)
	Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

View original content to download multimedia:https://www.prnewswire.com/news-releases/lillys-ebglyss-lebrikizumab-lbkz-is-the-first-and-only-selective-il-13-inhibitor-to-deliver-positive-phase-3-outcomes-in-patients-aged-six-months-to-18-years-with-moderate-to-severe-atopic-dermatitis-302714000.html

SOURCE Eli Lilly and Company

FAQ

What were the Week 16 efficacy results for EBGLYSS in ADorable-1 (LLY) reported March 16, 2026?

EBGLYSS produced EASI-75 63%, IGA 0,1 44%, EASI-90 39% and Pruritus NRS ≥4 35% at Week 16. According to Lilly, these topline numbers reflect co-primary and key secondary endpoint achievement in pediatric patients aged six months to 18 years.

How did EBGLYSS safety compare to adult studies in the ADorable-1 pediatric trial (LLY)?

Safety was reported as consistent with adult and adolescent studies, with no new safety signals observed. According to Lilly, the most common adverse events were upper respiratory infections and nasopharyngitis, and no injection site pain was reported in the trial.

Will Lilly (LLY) seek pediatric label updates for EBGLYSS after ADorable-1 results?

Yes. Lilly plans to submit ADorable-1 data to U.S. and global regulators for potential pediatric label updates. According to Lilly, regulatory submissions are planned based on these topline Week 16 results and the ongoing ADorable program.

Did the ADorable-1 trial allow use of topical corticosteroids during EBGLYSS testing (LLY)?

Yes. Topical corticosteroids were required beginning two weeks before randomization and during the 16-week study, though they could be decreased or stopped after achieving IGA ≤2. According to Lilly, this was part of the trial design for all participants.

What next steps did Lilly (LLY) announce after the ADorable-1 pediatric results for EBGLYSS?

Lilly said the ADorable clinical program is ongoing and that additional ADorable-1 and ADorable-2 52-week extension results will be disclosed later this year. According to Lilly, these follow-up data will inform regulatory submissions and longer-term safety and durability assessments.